Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Sonnet Biotherapeutics Holdings Inc

SONN:NAQ

Sonnet Biotherapeutics Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.9439
  • Today's Change-0.056 / -5.61%
  • Shares traded37.30k
  • 1 Year change-69.25%
  • Beta0.4902
Data delayed at least 15 minutes, as of Sep 23 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. Its technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. It designed the FHAB construct to improve drug accumulation in tumors, and to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12, covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical stage asset, SON-080, is the native human version of IL-6 that is manufactured in Chinese Hamster Ovary cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy and Diabetic Peripheral Neuropathy. Its pipeline also includes SON-1210, SON-1410 and SON-3015.

  • Revenue in USD (TTM)55.89k
  • Net income in USD-7.99m
  • Incorporated1999
  • Employees12.00
  • Location
    Sonnet Biotherapeutics Holdings Inc100 Overlook Center, Suite 102PRINCETON 08540United StatesUSA
  • Phone+1 (609) 375-2227
  • Fax+1 (302) 636-5454
  • Websitehttps://www.sonnetbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
China Pharma Holdings Inc6.25m-4.40m3.66m231.00--0.4941--0.5859-0.6254-0.62540.63790.43170.4172.3423.5727,047.32-29.39-29.66-59.89-55.25-25.896.47-70.48-73.090.2449-21.220.3494---13.48-10.6822.50---25.78--
Sunshine Biopharma Inc30.48m-3.68m3.76m44.00--0.1665--0.1232-194.01-194.011,017.8520.071.063.3310.19692,772.50-12.75-101.52-15.41-137.0430.4135.47-12.07-165.333.26--0.00--454.42--83.15--110.99--
Evoke Pharma Inc7.53m-6.53m3.87m4.00--1.45--0.5136-16.23-16.2311.243.630.71280.43074.971,881,428.00-61.83-100.48-136.53-151.1096.97---86.75-480.521.22-19.910.6523--106.51--5.25------
Tian'an Pharmaceutical Co Ltd10.65m3.14m4.24m--0.02360.00511.160.39810.22460.22460.76111.03----------------68.54--29.51--13.3625.660.00--50.51--106.71------
Sonoma Pharmaceuticals Inc12.70m-4.56m4.26m172.00--0.6074--0.3352-10.07-10.0720.985.240.8592.914.4773,831.40-30.85-29.36-41.88-40.6538.1738.00-35.91-30.932.47--0.0394---4.05-7.666.13---29.84--
GT Biopharma Inc0.00-11.35m4.40m2.00--0.7993-----7.72-7.720.002.470.00----0.00-82.84-205.36-120.73--------------0.00------63.62------
Processa Pharmaceuticals Inc0.00-10.22m4.43m13.00--0.6476-----5.36-5.360.002.100.00----0.00-115.58-84.35-133.48-90.03------------0.0016------59.45---34.05--
Silo Pharma Inc72.12k-3.45m4.66m3.00--0.6495--64.67-1.16-1.180.02421.600.0079----24,040.00-37.69-24.90-43.50-26.3991.9082.79-4,777.02-2,757.85----0.00--0.00--7.07------
Titan Pharmaceuticals Inc4.00k-5.46m4.83m4.00--1.21--1,207.93-6.59-6.590.00494.370.0016--0.17021,000.00-211.58-96.80-368.99-156.65-----136,525.00-406.26---309.960.00---66.97-51.1645.43---65.61--
CYANOTECH CORP23.82m-5.10m4.87m77.00--0.4563--0.2045-0.7549-0.75493.561.530.88952.0512.12309,389.60-19.04-3.46-29.60-4.4624.7234.54-21.41-3.580.3354-6.610.377---0.4616-5.24-53.11---6.42--
Sonnet Biotherapeutics Holdings Inc55.89k-7.99m4.91m12.00--1.88--87.86-3.02-3.020.01440.50170.0071--0.08814,657.50-100.88---255.30-------14,287.67-----331.070.00---57.76--36.64------
Stemtech Corp5.37m-5.11m5.04m45.00------0.9395-0.0518-0.05180.0529-0.03591.338.3942.31---126.26------77.87---95.16--0.065-2.59----7.94--36.45------
AgriFORCE Growing Systems Ltd57.60k-15.05m5.08m7.00--0.4007--88.12-5.81-5.810.00370.13430.0034--1.218,228.57-88.79-78.95-124.14-109.8617.86---26,121.49-243,182.501.24-1.280.0789------8.85--48.61--
Universe Pharmaceuticals Inc32.31m-6.16m5.98m225.00--0.0232--0.1852-1.70-1.708.9110.910.57277.932.50143,594.40-10.925.31-14.347.0731.9346.26-19.086.252.43-28.050.12180.00-19.522.5329.46---21.17--
Hoth Therapeutics Inc0.00-7.46m6.31m2.00--0.524-----1.69-1.690.001.740.00----0.00-67.99-157.07-76.33-177.32------------0.00------31.01------
Data as of Sep 23 2024. Currency figures normalised to Sonnet Biotherapeutics Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

3.27%Per cent of shares held by top holders
HolderShares% Held
G1 Execution Services LLCas of 31 Mar 202434.45k1.11%
Virtu Americas LLCas of 30 Jun 202432.69k1.05%
Geode Capital Management LLCas of 30 Jun 202416.70k0.54%
The Vanguard Group, Inc.as of 31 Mar 202414.73k0.47%
Tower Research Capital LLCas of 31 Mar 20242.72k0.09%
BlackRock Fund Advisorsas of 31 Mar 2024520.000.02%
Citigroup Global Markets, Inc. (Investment Management)as of 31 Mar 202438.000.00%
Wells Fargo Bank, NA (Private Banking)as of 31 Mar 202422.000.00%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 20246.000.00%
Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 31 Mar 20246.000.00%
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.